BOTOX® Cosmetic (Botulinum Toxin Type A) Fact Sheet

•
More than 13 million aesthetic procedures with BOTOX® Cosmetic (botulinum toxin type A) have
been administered since the product was first approved in 2002 in the United States for temporary
treatment of moderate to severe glabellar lines (the vertical “frown lines” between the eyebrows) in
adults 18 to 65.i
•
According to the American Society for Aesthetic Plastic Surgery (ASAPS), more than three million
BOTOX® Cosmetic treatments were administered in 2006 alone.ii
•
Ninety-seven percent of patients were definitely satisfied with BOTOX® Cosmetic treatments,
according to a survey of approximately 1,000 patients conducted by the research arm of ASAPS.iii
•
BOTOX® Cosmetic, approved for the temporary treatment of glabellar lines, is the same medicine
that is used to treat patients with neurological conditions under the name BOTOX®. It is, however,
administered in much smaller doses for aesthetic use. The approved doses of BOTOX® for medical
uses are significantly greater than the approved dose for an aesthetic procedure.
•
BOTOX® Cosmetic is a simple, minimally invasive injectable treatment that creates a temporary
smoothed and improved appearance of the wrinkle-causing muscles between the brows that lasts up
to four months. Most side effects are temporary and typically associated with the injection itself, such
as localized pain, tenderness, redness and/or bruising. (See full safety information provided below).
•
Since its first approval more than 18 years ago, reports of serious adverse events in patients
receiving BOTOX® have been rare.
•
BOTOX® Cosmetic should only be administered by a licensed health care professional (HCP) who is
well trained in the anatomy of the face.